EP Patent

EP2934514A1 — Transthyretin stabilizers and their use for inhibiting transthyretin amyloidosis and protein-protein interactions

Assigned to Leland Stanford Junior University · Expires 2015-10-28 · 11y expired

What this patent protects

Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of prote…

USPTO Abstract

Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.

Drugs covered by this patent

Patent Metadata

Patent number
EP2934514A1
Jurisdiction
EP
Classification
Expires
2015-10-28
Drug substance claim
No
Drug product claim
No
Assignee
Leland Stanford Junior University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.